with special arrangements for clinical governance, consent and research for patients who are well enough for surgical mitral valve leaflet repair to treat their mitral regurgitation, or in the context of research for patients who are not well enough for surgical mitral valve leaflet repair to treat their mitral regurgitation. 1.2 Clinicians wishing to undertake percutaneous mitral valve leaflet repair for mitral regurgitation in patients who are well enough for surgical mitral valve leaflet repair to treat their mitral regurgitation should take the following actions.
Inform the clinical governance leads in their Trusts.
Ensure that patients and their carers understand the uncertainty about the procedure's safety and efficacy and provide them with clear written information. In addition, the use of NICE's information for patients ('Understanding NICE guidance') is recommended. Patient selection and treatment should be carried out in specialist units (with access to emergency cardiac surgery) by a multidisciplinary team, including an interventional cardiologist (with expertise in echocardiography or with support from an echocardiologist) and a cardiac surgeon.
1.6
This procedure should only be carried out by clinicians with specific training. 1.7 NICE is aware of current clinical trials involving this procedure, and may review the procedure on publication of further evidence.
2
The procedure The procedure The aim of percutaneous mitral valve leaflet repair is to keep the two valve leaflets more closely apposed to each other during systole, thereby reducing regurgitation.
2.2.2
Percutaneous mitral valve leaflet repair is undertaken with the patient under general anaesthesia. Under fluoroscopy and transoesophageal echocardiography guidance, a catheter is advanced through the femoral vein to the right atrium and via a transseptal puncture into the left atrium. The mitral leaflets are partially clipped to each other (more than one clip may be used).
Imaging is used to assess whether the reduction in mitral regurgitation is adequate. The clips may be repositioned if necessary.
2.2.3
Various devices have been used for this procedure. For more detailed information on the evidence, see the overview.
Percutaneous mitral valve leaflet repair for mitral regurgitation (IPG309)
Efficacy

2.3.1
In a multicentre case series of 107 patients with mitral regurgitation of grade 3 or 4 at baseline, there was successful clip placement (not otherwise defined) in 90% (96/107) of patients. Technical success (defined as a reduction in mitral regurgitation to grade '2+' or lower, based on the American Society of Echocardiography guidelines) was achieved in 74% (79/107) of patients. Of these patients, 77% (absolute figures not stated) and 66% (50/76) maintained the reduction in mitral regurgitation to grade 2+ or lower at hospital discharge and 12-month follow-up, respectively.
2.3.2
A further publication on this case series reported that mean mitral valve pressure gradient increased from 1.79 mmHg at baseline to 3.56 mmHg at 12-month follow-up (n = 13).
2.3.3
Specialist Advisers considered key efficacy outcomes to include successful clip deployment, reduction of mitral regurgitation, durability of outcome, left ventricular dimensions and function, need for subsequent mitral valve surgery and quality of life.
Safety
2.4.1
In the case series of 107 patients, 10 had a major adverse event within 30 days.
Partial clip detachment (that is, from 1 of the 2 valve leaflets) occurred in 9% (10/107) of patients: 3 during the procedure, 1 before hospital discharge, 5 between discharge and 30-day follow-up, and 1 after 30 days. Partial clip detachment requiring further surgery before hospital discharge was reported in a patient in the case series of 47 patients (exact timing of event not stated).
2.4.2
In the case series of 107 patients, a patient had a non-embolic stroke with neurological deficit lasting 72 hours (resolved within 30 days).
2.4.3
Specialist Advisers considered theoretical adverse events to include leaflet tearing, clip embolism, partial clip detachment, complications from vascular access, cardiac tamponade from attempted transseptal puncture, atrial septal defect, and scar formation around clips, causing mitral stenosis. This guidance was developed using the NICE interventional procedure guidance process.
It has been incorporated into the NICE pathway on chronic heart failure, along with other related guidance and products.
We have produced a summary of this guidance for patients and carers. Information about the evidence it is based on is also available.
Changes since publication
Changes since publication 8 May 2012: minor maintenance.
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